Molecular and Cellular Biochemistry

, Volume 312, Issue 1–2, pp 71–80 | Cite as

Chemoresistance in gliomas



Despite improved knowledge and advanced treatments of gliomas, the overall survival rate for glioma patients remains low. Gliomas comprise of significant cell heterogeneity that contains a large number of multidrug resistant (MDR) phenotypes and cancer stem cells (CSCs), a combination that may contribute to the resistance to treatment. This article reviews the MDR related genes, major-vault protein (MVP), anti-apoptotic protein (Bcl-2) and the molecular mechanisms that may contribute to chemoresistance, in addition to the upregulated MDR phenotypes present in CSCs that has recently been identified in gliomas. Moreover, future potential therapies that modulate MDR phenotypes and CSCs are also reviewed. An improved understanding of MDR may lead to a combined treatment, targeting both CSCs and their protective MDR phenotypes leading eventually to attractive strategies for the treatment of gliomas.


Glioma Brain tumour Multidrug resistance Cancer stem cells 



The authors would like to thank Dr Leroy Shervington for editing the script and Andrew Bamber, David Burnham, Clare Christopher and Christopher Clark for their contribution. This work was supported by a grant from the University of Central Lancashire.


  1. 1.
    Coleman MP, Rachet B, Woods LM, Mitry E, Riga M, Cooper N, Quinn M J, Brenner H, Esteve J (2004) Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. Br J Cancer 90:1367–1373PubMedGoogle Scholar
  2. 2.
    Darling J (2004) In vitro culture of malignant brain tumors. In: Pfragner R, Freshney I (eds) Culture of human tumor cells. Wiley-Liss Inc., Verlag GMbH, pp 349–372Google Scholar
  3. 3.
    Bredel M (2001) Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 35:161–204PubMedGoogle Scholar
  4. 4.
    Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284PubMedGoogle Scholar
  5. 5.
    Kroll DJ (1995) Circumventing antineoplastic drug resistance: when tumor cells just say “no” to drugs. Am J Pharm Educ 59:184–191Google Scholar
  6. 6.
    Biemans-Oldehinkel E, Doeven MK, Poolman B (2006) ABC transporter architecture and regulatory roles of accessory domains. FEBS Lett 580:1023–1035PubMedGoogle Scholar
  7. 7.
    Bunting KD (2002) ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells. 20:11–20PubMedGoogle Scholar
  8. 8.
    Dean M, Rzhetsky A, Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11:1156–1166PubMedGoogle Scholar
  9. 9.
    Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58PubMedGoogle Scholar
  10. 10.
    Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, Shen DW, Gottesman MM, Pastan I (1986) Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83:4538–4542PubMedGoogle Scholar
  11. 11.
    Spiegl-Kreinecker S (2002) Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance Protein 1 in human brain tumor cells and astrocytes. J Neuro-Oncology 57:27–36Google Scholar
  12. 12.
    Bahr O, Rieger J, Duffner F, Meyermann R, Weller M, Wick W (2003) P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells. Brain Pathol 13:482–494PubMedCrossRefGoogle Scholar
  13. 13.
    Mousseau M, Schaerer R, Pasquier B, Chauvin C, Nissou MF, Chaffanet M, Plantaz D, Benabid A (1993) A study of the expression of four chemoresistance-related genes in human primary and metastatic brain tumours. Eur J Cancer 29A:753–759PubMedGoogle Scholar
  14. 14.
    Abe T, Mori T, Wakabayashi Y, Nakagawa M, Cole SP, Koike K, Kuwano M, Hori S (1998) Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J Neurooncol 40L:11–18Google Scholar
  15. 15.
    Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V (1991) P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608–1614PubMedCrossRefGoogle Scholar
  16. 16.
    Chou PM, Reyes-Mugica M, Barquin N, Yasuda T, Tan X, Tomita T (1995) Multidrug resistance gene expression in childhood medulloblastoma: correlation with clinical outcome and DNA ploidy in 29 patients. Pediatr Neurosurg 23:283–291PubMedGoogle Scholar
  17. 17.
    Korshunov A, Sycheva R, Timirgaz V, Golanov A (1999a) Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases. J Neurooncol 45:219–227PubMedGoogle Scholar
  18. 18.
    Andersson U, Malmer B, Bergenheim AT, Brännström T, Henriksson R (2004) Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol 23:21–27PubMedGoogle Scholar
  19. 19.
    Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 258:1650–1654PubMedGoogle Scholar
  20. 20.
    Deeley RG, Cole SP (2006) Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett 580:1103–1111PubMedGoogle Scholar
  21. 21.
    Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902–5910PubMedGoogle Scholar
  22. 22.
    Leier I, Jedlitschky G, buchholz U, Keppler D (1994) Characterization of the ATP-dependent leukotriene C4 export carrier in mastocytoma cells. Eur J Biochem 220:599–606PubMedGoogle Scholar
  23. 23.
    Kuwano M, Toh S, Uchiumi T, Takano H, Kohno K, Wada M (1999) Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des 14:123–131PubMedGoogle Scholar
  24. 24.
    Cui Y, Konig J, Buchholz J, Spring H, Leier I, Keppler D (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929–937PubMedGoogle Scholar
  25. 25.
    Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D (1994) ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54:4833–4836PubMedGoogle Scholar
  26. 26.
    Benyahia B, Huguet S, Decleves X, Mokhtari K, Criniere E, Bernaudin JF, Scherrmann JM, Delattre JY (2004) Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1. J Neuro-Oncology 66:65–70Google Scholar
  27. 27.
    Nies AT, Jedlitschky G, Konig J, Herold-Mende C, Steiner HH, Schmitt HP, Keppler D (2004) Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 129:349–360PubMedGoogle Scholar
  28. 28.
    Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A, Vitellaro-Zuccarello L, Croci D, Boiardi A, Salmaggi A (2005) Expression of drug resistance protein Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 74:113–121PubMedGoogle Scholar
  29. 29.
    Haga S, Hinoshita E, Ikezaki K, Fukui M, Scheffer GL, Uchiumi T, Kuwano M (2001) Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma. Jpn J Cancer Res 92:211–219PubMedGoogle Scholar
  30. 30.
    Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665–15670PubMedGoogle Scholar
  31. 31.
    Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T (2001) The role of half-transporters in multidrug resistance. J Bioenerg Biomembr 33(6) 503–511PubMedGoogle Scholar
  32. 32.
    Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340–7358PubMedGoogle Scholar
  33. 33.
    Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE (2001) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7:145–152PubMedGoogle Scholar
  34. 34.
    Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper RJ, Taylor CG (2001) Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol 115:257–262PubMedGoogle Scholar
  35. 35.
    van der Kolk DM, Vellenga E, Scheffer GL, Muller M, Bates SE, Scheper RJ, de Vries EG (2002) Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukaemia. Blood 99:3763–3770PubMedGoogle Scholar
  36. 36.
    Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB (2003) The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J 17:2085–2087PubMedGoogle Scholar
  37. 37.
    Aronica E, Gorter JA, Redeker S, van Vliet EA, Ramkema M, Scheffer GL, Scheper RJ, van der V, Leenstra S, Baayen JC, Spliet WG, Troost D (2005) Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 46:849–857Google Scholar
  38. 38.
    Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH (1993) Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53:1475–1479PubMedGoogle Scholar
  39. 39.
    Chugani DC, Rome LH, Kedersha NL (1993) Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci 106:23–29PubMedGoogle Scholar
  40. 40.
    Slesina M, Inman EM, Rome LH, Volknandt W (2005) Nuclear localization of the major vault protein in U373 cells. Cell Tissue Res 321:97–104PubMedGoogle Scholar
  41. 41.
    Slovak ML, Ho JP, Cole SP, Deeley RG, Greenberger L, de Vries EG, Broxterman HJ, Scheffer GL, Scheper RJ (1995) The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 55:4214–4219PubMedGoogle Scholar
  42. 42.
    Scheffer GL, Wijingaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM (1995) The drug resistance-related protein LRP is the human major vault protein. Nat Med 1:578–582PubMedGoogle Scholar
  43. 43.
    Hamill DR, Suprenant KA (1997) Characterization of the sea urchin major vault protein: a possible role for vault ribonucleoprotein particles in nucleocytoplasmic transport. Dev Biol 190:117–128PubMedGoogle Scholar
  44. 44.
    Abbondanza C, Rossi V, Roscigno A, Gallo L, Belsito A, Piluso G, Medici N, Nigro V, Molinari AM, Moncharmont B, Puca GA (1998) Interaction of vault particles with estrogen receptor in the MCF-7 breast cancer cell. J Cell Biol 141:1301–1310PubMedGoogle Scholar
  45. 45.
    Kong LB, Siva AC, Rome LH, Stewart PL (1999) Structure of the vault, a ubiquitous cellular component. Structure 7:371–379PubMedGoogle Scholar
  46. 46.
    Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jager U, Geissler K, Lechner K, Pirker R (1998) Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 91:1508–1513PubMedGoogle Scholar
  47. 47.
    Ohsawa M, Ikura Y, Fukushima H, Shirai N, Sugama Y, Suekane T, Hirayama M, Hino M, Ueda M (2005) Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 68:422–431PubMedGoogle Scholar
  48. 48.
    Rybarova S, Hajdukova M, Hodorova I, Kocisova M, Boor A, Brabencova E, Kasan P, Biros E, Mojzis J, Mirossay L (2004) Expression of the multidrug resistance associated protein 1 (MRP1) and the lung resistance-related protein (LRP) in human lung cancer. Neoplasma 51:169–174PubMedGoogle Scholar
  49. 49.
    Aronica E, Gorter JA, van Vliet EA, Spliet WG, van Veelen CW, van Rijen PC, Leenstra S, Ramkema MD, Scheffer GL, Scheper RJ, Sisodiya SM, Troost D (2003) Overexpression of the human major vault protein in gangliogliomas. Epilepsia 44:1166–1175PubMedGoogle Scholar
  50. 50.
    Berger W, Spiegl-Kreinecker S, Buchroithner J, Elbling L, Pirker C, Fischer J, Micksche M (2001) Overexpression ofthe human major vault protein in astrocytic brain tumor cells. Int J Cancer 94:377–382PubMedGoogle Scholar
  51. 51.
    Tews DS, Nissen A, Kulgen C, Gaumann AK (2000) Drug resistance-associated factors in primary and secondary glioblastoma and their precursor tumors. J Neuro-oncology 50:227–237Google Scholar
  52. 52.
    Sisodiya SM, Martinian L, Scheffer GL, van der Valk P, Cross JH, Scheper RJ, Harding BN, Thom M (2003) Major vault protein a marker of drug resistance, is upregulated in refractory epilepsy. Epilepsia 44:1388–1396PubMedGoogle Scholar
  53. 53.
    Wang XM, Xin H, Yang Z, Zhao W, Yang G, Liu J, Tang W, Zhang Q, Han D, Yu R (2004) Clinical study on treatment of advanced stage non-small cell lung cancer by guben xiaoliu capsule. Zhongguo Zhong Xi Yi Jie He Za Zhi 24:986–988PubMedGoogle Scholar
  54. 54.
    Klunder JW, Komdeur R, Van der Graaf WT, De Bont EJ, Hoekstra HJ, Van den Berg E, Molenaar WM (2003) Expression of multidrug resistance–associated proteins in rhabdomyosarcomas before and after chemotherapy: the relationship between lung resistance–related protein (LRP) & differentiation. Hum Pathol 34:150–155PubMedGoogle Scholar
  55. 55.
    Izquierdo MA, Scheffer GL, Flens MJ, Shoemaker RH, Rome LH, Scheper RJ (1996) Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology 19:191–197PubMedGoogle Scholar
  56. 56.
    Siva AC, Raval-Fernandes S, Stephen AG, LaFemina MJ, Scheper RJ, Kickhoefer VA, Rome LH (2001) Up-regulation of vaults may be necessary but not sufficient for multidrug resistance. Int J Cancer 92:195–202PubMedGoogle Scholar
  57. 57.
    Sasaki T, Hankins GR, Helm GA (2002) Major vault protein/lung resistance-related protein (MVP/LRP) expression in nervous system tumors. Brain Tumor Path 19:59–62Google Scholar
  58. 58.
    Koda M, Reszec J, Sulkowska M, Kanczuga-Koda L, Sulkowski S (2004) Expression of the insulin-like growth factor-I receptor and proapoptotic Bax and Bak proteins in human colorectal cancer. Ann NY Acad Sci 1030:377–383PubMedGoogle Scholar
  59. 59.
    Fels C, Schafer C, Huppe B, Bahn H, Heidecke V, Kramm CM, Lautenschlager C, Rainov NG (2000) Bcl-2 expression in higher-grade human glioma: a clinical and experimental study. J Neuro-oncology 48:207–216Google Scholar
  60. 60.
    Karmakar S, Weinberg MS, Banik NL, Patel SJ, Ray SK (2006) Activation of multiple molecular mechanisms for apoptosis in human malignant glioblastoma T98G and U87MG cells treated with sulforaphane. Neuroscience 141:1265–1280PubMedGoogle Scholar
  61. 61.
    Huang DC, O’Reilly LA, Strasser A, Cory S (1997) The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 16:4628–4638PubMedGoogle Scholar
  62. 62.
    Vairo G, Innes KM, Adams JM (1996) Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 13:1511–1519PubMedGoogle Scholar
  63. 63.
    Greider C, Chattopadhyay A, Parkhurst C, Yang E (2002) BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases. Oncogene 21:7765–7775PubMedGoogle Scholar
  64. 64.
    Bélanger S, Côté M, Lane D, L’Espérance S, Rancourt C, Piché A (2005) Bcl-2 decreases cell proliferation and promotes accumulation of cells in S phase without affecting the rate of apoptosis in human ovarian carcinoma cells. Gynecol Oncol 97:796–806PubMedGoogle Scholar
  65. 65.
    Tyagi D, Sharma BS, Gupta SK, Kaul D, Vasishta RK, Khosla VK (2002) Expression of Bcl2 proto-oncogene in primary tumors of the central nervous system. Neurol India 50:290–294PubMedGoogle Scholar
  66. 66.
    Lu Z, Wu Z, Mo Y (2006) Regulation of bcl-2 expression by Ubc9. Exp Cell Res 312:1865–1875PubMedGoogle Scholar
  67. 67.
    Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A (1995) Protooncogene bcl-2 Gne transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95:2633–2643PubMedGoogle Scholar
  68. 68.
    Riger J, Roth W, Glaser T, Winter S, Rieger L, Dichgans J, Weller M (1999) Glioblastoma multiforme: mechanisms of resistance to chemotherapy. Neurol Psychiatry Brain Res 7:37–46Google Scholar
  69. 69.
    Korshunov A, Golanov A, Sycheva R, Pronin I (1999b) Prognostic value of the immunoexpression of chemoresistance-related proteins in cerebral goioblastomas: an analysis of 168 cases. J Clin Pathol 52:574–580PubMedCrossRefGoogle Scholar
  70. 70.
    Newcomb EW, Bhalla SK, Parrish CL, Hayes RL, Cohen H, Miller DC (1997) bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropathol 94:369–375PubMedGoogle Scholar
  71. 71.
    Prowit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G (1995) Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia 9:1191–1198Google Scholar
  72. 72.
    Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ (1996) Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10:456–459PubMedGoogle Scholar
  73. 73.
    Streffer JR, Rimner A, Rieger J, Naumann U, Rodemann HP, Weller M (2002) BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells. J Neurooncol 56:43–49PubMedGoogle Scholar
  74. 74.
    Bruce WR, Van Der Gaag H (1963) A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 199:79–80PubMedGoogle Scholar
  75. 75.
    Al-Hajj M, Wicha MS, ito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci US 100:3983–3988Google Scholar
  76. 76.
    Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE (1997) Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA 94:5320–5325PubMedGoogle Scholar
  77. 77.
    Challen GA, Little MH (2006) A side order of stem cells: the SP phenotype. Stem Cells 24:3–12PubMedGoogle Scholar
  78. 78.
    Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK (2004) A distinct ‘‘side population’’ of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101:14228–14233PubMedGoogle Scholar
  79. 79.
    Kondo T, Setoguchi T, Taga T (2004) Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101:781–786PubMedGoogle Scholar
  80. 80.
    Wang JC, Dick JE (2005) Cancer stem cells: lessons from leukemia. Trends Cell Biol 15:494–501PubMedGoogle Scholar
  81. 81.
    Miller SJ, Lavker RM, Sun TT (2005) Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta 1756:25–52PubMedGoogle Scholar
  82. 82.
    Fomchenko EI, Holland EC (2005) Stem cells and brain cancer. Exp Cell Res 306:323–329PubMedGoogle Scholar
  83. 83.
    Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111PubMedGoogle Scholar
  84. 84.
    Chaudhary PM, Roninson IB (1991) Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85–94PubMedGoogle Scholar
  85. 85.
    Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7:1028–1034PubMedGoogle Scholar
  86. 86.
    Cai J, Cheng A, Luo Y, Lu C, Mattson MP, Rao MS, Furukawa K (2004) Membrane properties of rat embryonic multipotent neural stem cells. J Neurochem 88:212–226PubMedCrossRefGoogle Scholar
  87. 87.
    Platet N, Mayo J, Berger F, Hérodin F, Wion D (2007) Fluctuation of the SP/non-SP phenotype in the C6 glioma cell line. FEBS Lett 581:1435–1440PubMedGoogle Scholar
  88. 88.
    Robey RW, Polgar O, Deeken J, To KW, Bates SE (2007) ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 26:39–57PubMedGoogle Scholar
  89. 89.
    Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2− cancer cells are similarly tumorigenic. Cancer Res 65:6207–6219PubMedGoogle Scholar
  90. 90.
    Wei L, Cui L, Snider J, Rivkin M, Yu SS, Lee CS, Adams LD, Gottlieb DI, Johnson Jr EM, Yu SP, Choi DW (2005) Transplantation of embryonic stem cells overexpressing Bcl-2 promotes functional recovery after transient cerebral ischemia. Neurobiol Dis 19:183–193PubMedGoogle Scholar
  91. 91.
    Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67–71PubMedGoogle Scholar
  92. 92.
    Decleves X, Fajac A, Lehmann-Che J, Tardy M, Mercier C, Hurbain I, Laplanche JL, Bernaudin JF, Scherrmann JM (2002) Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int J Cancer 98:173–180PubMedGoogle Scholar
  93. 93.
    Matsumoto Y, Miyake K, Kunishio K, Tamiya T, Seigo N (2004) Reduction of expression of the multidrug resistance protein (MRP)1 in glioma cells by antisense phosphorothioate oligonucleotides. J Med Invest 51:194–201PubMedGoogle Scholar
  94. 94.
    Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, Mao Q (2006) Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58:374–383PubMedGoogle Scholar
  95. 95.
    Kitazono M, Okumura H, Ikeda R, Sumizawa T, Furukawa T, Nagayama S, Seto K, Aikou T, Akiyama S (2001) Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells. Int J Cancer 91:126–131PubMedGoogle Scholar
  96. 96.
    Manero F, Gautier F, Gallenne T, Cauquil N, Grée D, Cartron PF, Geneste O, Grée R, Vallette FM, Juin P (2006) The small organic compound HA14–1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 66:2757–2764PubMedGoogle Scholar
  97. 97.
    Zhu CJ, Li YB, Wong MC (2003) Expression of antisense bcl-2 cDNA abolishes tumorigenicity and enhances chemosesitivity of human malignant glioma cells. J Neurosci Res 74:60–66PubMedGoogle Scholar
  98. 98.
    Baguley BC (2006) Tumor stem cell niches: a new functional framework for the action of anticancer drugs. Recent Patents Anti-Cancer Drug Discov 1:121–127Google Scholar
  99. 99.
    Brown AB, Yang W, Schmidt NO, Carroll R, Leishear KK, Rainov NG, Black PM, Breakefield XO, Aboody KS (2003) Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin Hum Gene Ther 14:1777–1785PubMedGoogle Scholar
  100. 100.
    Irvin DK, Yuan X, Zhaohui Z, Tunici P, Yu JS (2006) Neural stem cells – a promising potential therapy for brain tumors. Curr Stem Cell Res Ther 1:79–84Google Scholar
  101. 101.
    Sell S (2004) Stem cell origin of cancer and differentiation therapy Crit Rev Oncol/Hematol 51:1–28Google Scholar
  102. 102.
    Tunici P, Irvin D, Liu G, Yuan X, Zhaohui Z, Ng H, Yu JS (2006) Brain tumor stem cells: new targets for clinical treatments? Neurosurg Focus 20:E27PubMedGoogle Scholar
  103. 103.
    Rittierodt M, Tschernig T, Harada K (2004) Modulation of multidrug-resistance-associated p-glycoprotein in human U-87 MG and HUV-ECC cells with antisense oligodeoxynucleotides to MDR1 mRNA. Pathobiology 71:123–128PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  1. 1.Brain Tumour North West, Faculty of ScienceUniversity of Central LancashirePrestonUK

Personalised recommendations